Payment overview · 2025
General Payments
$431.29
18 reported records · 7 companies
Healthcare provider profile · identity verified
Timothy Marshall Iliff, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MOBILE, AL · NPI 1366603748
Verified facts
What the public records show
CMS Open Payments records show Timothy Marshall Iliff, M.D. received $431.29 in general payments during 2025 across 18 reported records.
ViiV Healthcare Company accounted for 52.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lumigan by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Descovy by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Isentress by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $225.20 | 52.2% | 9 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $45.46 | 10.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.59 | 9.6% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $40.15 | 9.3% | 2 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $33.17 | 7.7% | 1 | 2025 |
| Melinta Therapeutics, LLC | Unresolved — no canonical attribution shown | $29.15 | 6.8% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.57 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $431.29 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $200.78 | 8 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $45.46 | 2 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $41.59 | 2 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $41.59 | 2 | 2025 |
Source payment records
|
|||||
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $33.17 | 1 | 2025 |
Source payment records
|
|||||
| Rezzayo Normalized: rezzayo |
Drug | Melinta Therapeutics, LLC | $29.15 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 565 | 54 |
| Eliquis | Apixaban | 442 | 36 |
| Atorvastatin Calcium | Atorvastatin Calcium | 371 | 55 |
| Furosemide | Furosemide | 366 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 261 | 36 |
| Potassium Chloride | Potassium Chloride | 209 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 28 |
| Lisinopril | Lisinopril | 201 | 32 |
| Losartan Potassium | Losartan Potassium | 201 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 197 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 34 |
| Memantine Hcl | Memantine Hcl | 181 | 22 |
| Donepezil Hcl | Donepezil Hcl | 179 | 25 |
| Daptomycin | Daptomycin | 177 | 29 |
| Gabapentin | Gabapentin | 172 | 45 |
| Trazodone Hcl | Trazodone Hcl | 168 | 24 |
| Sertraline Hcl | Sertraline Hcl | 157 | 27 |
| Famotidine | Famotidine | 147 | 19 |
| Levetiracetam | Levetiracetam | 140 | 14 |
| Vancomycin Hcl | Vancomycin Hcl | 133 | 28 |
| Cefepime Hcl | Cefepime Hcl | 129 | 32 |
| Ceftriaxone | Ceftriaxone Sodium | 125 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 116 | 30 |
| Carvedilol | Carvedilol | 110 | 18 |
| Omeprazole | Omeprazole | 103 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 16 |
| Xarelto | Rivaroxaban | 96 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 95 | 18 |
| Metformin Hcl | Metformin Hcl | 92 | 13 |
| Cephalexin | Cephalexin | 91 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | 25 |
| Allopurinol | Allopurinol | 84 | suppressed |
| Januvia | Sitagliptin Phosphate | 81 | suppressed |
| Cefazolin Sodium | Cefazolin Sodium | 80 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 23 |
| Prednisone | Prednisone | 77 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 16 |
| Diltiazem 24hr Er | Diltiazem Hcl | 75 | suppressed |
| Azithromycin | Azithromycin | 72 | 19 |
| Sodium Chloride | 0.9 % Sodium Chloride | 72 | 19 |
| Dovato | Dolutegravir Sodium/Lamivudine | 70 | suppressed |
| Meropenem | Meropenem | 68 | 15 |
| Mirtazapine | Mirtazapine | 65 | 14 |
| Sucralfate | Sucralfate | 65 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 63 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 32 |
| Ampicillin Sodium | Ampicillin Sodium | 62 | suppressed |
| Latanoprost | Latanoprost | 62 | suppressed |
| Ertapenem | Ertapenem Sodium | 61 | 14 |
| Meloxicam | Meloxicam | 55 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 54 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 52 | 13 |
| Midodrine Hcl | Midodrine Hcl | 52 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 52 | 19 |
| Fluconazole | Fluconazole | 51 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 47 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 13 |
| Clonidine Hcl | Clonidine Hcl | 45 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 28 |
| Tradjenta | Linagliptin | 42 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 27 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Pregabalin | Pregabalin | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | suppressed |
| Ivermectin | Ivermectin | 38 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 12 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 37 | suppressed |
| Baclofen | Baclofen | 36 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 36 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 35 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 17 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Olanzapine | Olanzapine | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 12 |
| Oxcarbazepine | Oxcarbazepine | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Tivicay | Dolutegravir Sodium | 33 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 32 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Rifampin | Rifampin | 30 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | 11 |
| Lidocaine | Lidocaine | 29 | suppressed |
| Methotrexate | Methotrexate Sodium | 29 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Simvastatin | Simvastatin | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 18 |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 24 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Nystop | Nystatin | 22 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Budesonide | Budesonide | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Isoniazid | Isoniazid | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Amikacin Sulfate | Amikacin Sulfate | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 18 | suppressed |
| Travoprost | Travoprost | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Mirabegron Er | Mirabegron | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Abacavir | Abacavir Sulfate | 14 | suppressed |
| Austedo | Deutetrabenazine | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Emtricitabine | Emtricitabine | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 14 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Eplerenone | Eplerenone | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Ceftazidime | Ceftazidime | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 12 | suppressed |
| Isentress | Raltegravir Potassium | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $431.29 · 18 records | ViiV Healthcare Company | APRETUDE, AVYCAZ, CABENUVA, DALVANCE, EMBLAVEO, Fetroja, NUZYRA, Rezzayo, TEFLARO, ZERBAXA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error